Parkwalk has invested in the spinout through both its Parkwalk Opportunities Fund and the University of Oxford Innovation Fund IV.
Oxford Endovascular, a UK-based medical device manufacturer focused on preventing brain aneurysms, today obtained an undisclosed amount of funding from investment firm Parkwalk Advisors.
Parkwalk, owned by commercialisation firm IP Group, contributed cash both through its Parkwalk Opportunities Fund and the University of Oxford Innovation Fund IV, the latter of which it manages on behalf of the institution.
Oxford Endovascular has created a device called Oxflow, which is able to divert blood away from brain aneurysms that are in danger of rupturing. Oxiflow is a mesh tube laser-cut from a nickel titanium alloy called nitinol.
The spinout previously raised $2.9m in 2016 from Oxford Sciences Innovation, the university venture fund of University of Oxford, and the University of Oxford Innovation Fund, which operated under the University of Oxford Isis Fund name at the time.
